MoonLake Immunotherapeutics (MLTX) Share-based Compensation (2021 - 2026)

MoonLake Immunotherapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $13.4 million in Q1 2026; TTM through Mar 2026 was $13.4 million, a 1290.29% increase from a year earlier, with the FY2024 full-year figure at $555000.0, down 92.19% from the prior year.
• Share-based Compensation rose to $13.4 million in Q1 2026 per MLTX's latest filing, from -$4.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $13.4 million in Q1 2026 and bottomed at -$4.8 million in Q4 2024.
• The 4-year median for Share-based Compensation is $2.0 million (2022), against an average of $2.4 million.
• Biggest YoY gain for Share-based Compensation was 249.17% in 2024; the steepest drop was 398.54% in 2024.
• Year by year, Share-based Compensation stood at $2.6 million in 2022, then sank by 38.17% to $1.6 million in 2023, then tumbled by 398.54% to -$4.8 million in 2024, then surged by 378.64% to $13.4 million in 2026.
• Per Business Quant, the three latest MLTX Share-based Compensation figures stand at $13.4 million (Q1 2026), -$4.8 million (Q4 2024), and $5.0 million (Q3 2024).